Does Aetna cover Wegovy, Zepbound, Ozempic or Mounjaro?

Aetna coverage, drug by drug

The table covers Aetna commercial plans, fully insured and self-funded, that use CVS Caremark. Each cell is the published rule, not a promise for your plan, which can differ.

Aetna commercial coverage of GLP-1 drugs by use, checked Oct 18, 2026

Drug	Weight loss	Heart risk	Sleep apnea	Type 2 diabetes
Wegovy (pen, HD, pill)	Only if the plan includes weight loss; preferred on Caremark templates [1] [11]	Caremark default and state-specific criteria: established heart disease, no type 2 diabetes [2] [4]	Not an approved Wegovy use [21]	Not an approved Wegovy use [21]
Zepbound	Only if the plan includes weight loss; pens back on Caremark templates Oct 1, 2026 [10]	Not an approved Zepbound use [22]	Caremark criteria: AHI 15+, BMI 30+ [3]	Not an approved Zepbound use [22]
Ozempic	No weight-loss route in the diabetes policy [7]	Through the diabetes policy only [6]	Not an approved use [18]	Prior authorization with lab proof of diabetes, 36 months [6] [7]
Mounjaro	No weight-loss route in the diabetes policy [7]	Through the diabetes policy only [6]	Not an approved use [19]	Prior authorization with lab proof of diabetes, 36 months [6] [7]

Why many Aetna members are excluded

Weight-loss drug coverage at Aetna is a choice the employer or plan makes, not a default. Aetna's own policy bulletin says many of its plans exclude these drugs ^[1]. Employer surveys show how uneven that choice is: in KFF's 2025 survey of firms that offer health benefits, 43% of firms with 5,000 or more workers covered GLP-1s primarily for weight loss, compared with 16% of firms with 200 to 999 workers ^[20].

If you bought an individual plan, the answer changed in 2026: Aetna left the ACA exchanges for 2026, affecting about 1 million members in 17 states ^[8]. People who had Aetna marketplace coverage in 2025 are now with another insurer, whose rules apply. Compare Blue Cross Blue Shield, UnitedHealthcare and Cigna, or the full insurer coverage tracker. Drug-level guides: Wegovy insurance and Zepbound insurance.

The criteria Caremark applies for Aetna

Two sets of criteria show up for Aetna members. Caremark's default forms for Wegovy (4774-C) and Zepbound (6947-C) use the same core rules as the July 1, 2025 Zepbound policy Aetna published for non-Medicare plans ^{[2] [3] [5]}. Aetna plans in certain states use a stricter "Specific States" policy (5098-C; the file name reads 5089-C), which does not name the states ^[4].

Aetna weight-loss prior authorization: default and state-specific criteria

Rule	Caremark default (Wegovy 4774-C, Zepbound 6947-C)	Aetna state-specific (5098-C)
Age	18 or older [2]	18 or older [4]
BMI to start	30 or higher, or 27 or higher with a weight-related condition [2] [3]	40 or higher, or 35 or higher with at least one weight-related condition [4]
Lifestyle program	At least 6 months in a comprehensive weight management program before the drug [2]	Actively enrolled in a weight loss program with diet and activity, documented [4]
First approval	8 months (Wegovy pill 6 months) [2]; Zepbound 8 months [3]	8 months for Foundayo, Wegovy injection and Zepbound; Wegovy pill 6 months [4]
Renewal	After 3 months at a stable maintenance dose with at least 5% loss; 12 months [2] [3]	At least 5% loss after 12 weeks at a stable maintenance dose [4]
Drugs listed	Wegovy pen, HD and pill; Zepbound pens [2] [3]	Includes Foundayo and Wegovy tablets [4]

For sleep apnea, Caremark's Zepbound criteria require an apnea-hypopnea index (AHI) of 15 or more and a current BMI of 30 or more, with a 6-month first approval and 12-month renewals ^[3]. Caremark's default Wegovy criteria and the state-specific policy both list Wegovy for heart risk for adults with established heart disease who do not have type 2 diabetes and are on standard heart therapy ^{[2] [4]}. The state policy also requires a BMI of 27 or more and points people with diabetes to Ozempic for heart benefit ^[4].

Ozempic and Mounjaro on Aetna

Aetna's diabetes GLP-1 policy, 5694-D, covers Ozempic, Rybelsus, Trulicity, Victoza, Byetta, Bydureon BCise and Mounjaro for type 2 diabetes ^[6]. Approval needs a type 2 diabetes diagnosis plus documentation of one of: an A1C of 6.5% or higher, a 2-hour glucose of 200 or higher on a glucose tolerance test, symptoms of high blood sugar with a random glucose of 200 or higher, or a fasting glucose of 126 or higher ^{[6] [7]}. Approvals last 36 months. There is no metformin trial requirement, and Caremark's version lets the claim pay without prior authorization when pharmacy records already show metformin or certain other diabetes drugs ^[7].

The version on Aetna's site is dated May 2023 ^[6]; Caremark's current default version (P05-2025) has the same criteria ^[7]. We could not confirm that every Aetna plan uses the 2025 version. The policy offers no route for weight loss or prediabetes alone; for weight loss, the plan looks at Wegovy or Zepbound instead. See Ozempic insurance and Ozempic vs Mounjaro.

Timeline: Aetna and Caremark changes

• Oct 1, 2026: Zepbound returns to Caremark commercial template formularies as "an additional preferred option" ^[10]. Members switching need a new prescription and prior authorization, as one plan sponsor, NRECA, told its members ^[12].
• July 1, 2026: the Medicare GLP-1 Bridge starts for Part D members, including Aetna Medicare Advantage drug plans ^[13].
• June 1, 2026: Caremark removes its new-to-market block on Foundayo ^[10].
• May 28, 2026: CVS announces the Zepbound return ^[10]; Wegovy injection and pill keep preferred status ^[11].
• March 10, 2026: Aetna last reviews its weight-loss policy bulletin, CPB 0039 ^[1].
• Jan 1, 2026: Aetna no longer sells ACA exchange plans ^[8].
• July 1, 2025: Caremark templates prefer Wegovy and remove Zepbound ^[9].
• May 1, 2025: CVS announces the exchange exit ^[8].

Checking your Aetna benefits

1. Call the pharmacy number on your Aetna card and ask one question first: does my plan include weight-loss drugs? If not, a weight-loss request is likely to be denied whatever your BMI ^[1].
2. Ask which criteria apply: Caremark default or the state-specific policy with a BMI 40 floor ^{[2] [4]}.
3. Ask about the 6-month program. Keep records of any dietitian, program or clinic visits, since the default criteria require them before the drug ^[2].
4. For Zepbound, ask whether your plan adopted Caremark's Oct 1, 2026 change; sponsors can customize ^[10].
5. For Ozempic or Mounjaro, have your prescriber attach the lab result that confirms type 2 diabetes ^[6].

When Aetna denies the request

Start with the denial letter: it says whether the plan excludes the drug or you did not meet a criterion. A missing program record or BMI can be fixed and resent. Appeal with your prescriber by the date on the letter. On plans that kept Wegovy as the only preferred drug, CVS said in 2025 that members who had intolerable side effects on Wegovy, or did not lose enough weight, could request a formulary exception for a different weight-loss drug, reviewed case by case ^[9].

Self-pay prices as of Oct 17, 2026: Wegovy pens $349 a month, Wegovy HD $399 and the Wegovy pill $149 to $299 on NovoCare, with $199 for each of a new self-pay patient's first two starting-dose pen fills through Dec 31, 2026 ^[15]. Zepbound on LillyDirect costs $299 to $449 per 28 days; the $449 price for 7.5 mg and up needs a refill within 45 days, or it rises to as much as $699 ^[16]. If an Aetna commercial plan covers the drug, manufacturer cards can cut the copay to as little as $25 ^{[15] [17]}. Ozempic self-pay is $349 a month, or $499 for the 2 mg dose ^[18]. Compare channels on Wegovy cost, Zepbound cost and the GLP-1 price tracker.

Aetna Medicare members

Aetna Medicare Advantage drug plans follow federal Part D rules, which exclude drugs used only for weight loss. Since July 1, 2026, the CMS Medicare GLP-1 Bridge covers Wegovy, Foundayo and the Zepbound KwikPen for weight management at $50 a month through Dec 31, 2027, for people 18 or older who meet its BMI rules ^{[13] [14]}. People with type 2 diabetes, moderate to severe sleep apnea or MASH are not eligible; their Part D plan may cover a GLP-1 for that condition ^[13]. We did not check Aetna's 2026 Part D drug lists. More on Medicare and GLP-1s.

See how other insurers compare